Literature DB >> 15109060

Immune modulation of the pulmonary hypertensive response to bacterial lipopolysaccharide (endotoxin) in broilers.

R F Wideman1, M E Chapman, W Wang, G F Erf.   

Abstract

The lungs of broilers are constantly challenged with lipopolysaccharide (LPS, endotoxin) that can activate leukocytes and trigger thromboxane A2 (TxA2)- and serotonin (5HT)-mediated pulmonary vasoconstriction leading to pulmonary hypertension. Among broilers from a single genetic line, some individuals respond to LPS with large increases in pulmonary arterial pressure, whereas others fail to exhibit any response to the same supramaximal dose of LPS. This extreme variability in the pulmonary hypertensive response to LPS appears to reflect variability in the types or proportions of chemical mediators released by leukocytes. Our research has confirmed that TxA2 and 5HT are potent pulmonary vasoconstrictors in broilers and that broilers hatched and reared together consistently exhibit pulmonary hypertension after i.v. injections of TxA2 or 5HT. Previous in vitro studies conducted using macrophages from different lines of chickens demonstrated innate variability in the LPS-stimulated induction of nitric oxide synthase (iNOS) followed by the onset of an LPS-refractory state. The NOS enzyme converts arginine to citrulline and nitric oxide (NO). It is known that NO produced by endothelial NOS serves as a key modulator of flow-dependent pulmonary vasodilation, and it is likely that NO generated by iNOS also contributes to the pulmonary vasodilator response. Accordingly, it is our hypothesis that the pulmonary hypertensive response to LPS in broilers is minimal when more vasodilators (NO, prostacyclin) than vasoconstrictors (TxA2, 5HT) are generated during an LPS challenge. Indeed, inhibiting NO production through pharmacological blockade of NOS with the inhibitor Nomega-nitro-L-arginine methyl ester modestly increased the baseline pulmonary arterial pressure and dramatically increased the pulmonary hypertensive response to LPS in all broilers evaluated. Innate differences in the effect of LPS on the pulmonary vasculature may contribute to differences in susceptibility of broilers to pulmonary hypertension syndrome (ascites).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15109060     DOI: 10.1093/ps/83.4.624

Source DB:  PubMed          Journal:  Poult Sci        ISSN: 0032-5791            Impact factor:   3.352


  6 in total

1.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

2.  Pulmonary vascular pressure profiles in broilers selected for susceptibility to pulmonary hypertension syndrome: age and sex comparisons.

Authors:  R F Wideman; M L Eanes; K R Hamal; N B Anthony
Journal:  Poult Sci       Date:  2010-09       Impact factor: 3.352

3.  Lipopolysaccharide modulation of thyrotropin-releasing hormone (TRH) and TRH-like peptide levels in rat brain and endocrine organs.

Authors:  Albert Eugene Pekary; Schetema A Stevens; Albert Sattin
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

4.  Intrapulmonary arteries respond to serotonin and adenosine triphosphate in broiler chickens susceptible to idiopathic pulmonary arterial hypertension.

Authors:  H A Kluess; J Stafford; K W Evanson; A J Stone; J Worley; R F Wideman
Journal:  Poult Sci       Date:  2012-06       Impact factor: 3.352

5.  The influence of enrofloxacin, florfenicol, ceftiofur and E. coli LPS interaction on T and B cells subset in chicks.

Authors:  Chrząstek Klaudia; Wieliczko Alina
Journal:  Vet Res Commun       Date:  2015-02-10       Impact factor: 2.459

6.  Effects of putative stressors and adrenocorticotropic hormone on plasma concentrations of corticosterone in market-weight male turkeys.

Authors:  Colin G Scanes; Kayla Hurst; Yvonne Thaxton; Gregory S Archer; Alice Johnson
Journal:  Poult Sci       Date:  2019-12-31       Impact factor: 4.014

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.